Trial results

A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL2

NCT06952530 on ClinicalTrials.gov · last registry update 2026-05-29

Closed to new participants; the 487 already enrolled are still being followed. Due to report September 2027, alongside 39 other tracked readouts that quarter. Primary outcome, as filed: Change from Baseline in office Systolic Blood Pressure (SBP). Sponsors move these dates routinely; any movement since this site started watching is listed below. orforglipron is approved in the US, but not for hypertension — a registration here is not an approval, and most drugs tested in a new condition never get one for it.

Status

ACTIVE_NOT_RECRUITING

Phase

P3

Drug

orforglipron

Foundayo

Sponsor

Eli Lilly and Company

Sponsor type

Industry

Enrollment

487

Started

2025-04-30

Primary completion

2027-09 estimated

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Change from Baseline in office Systolic Blood Pressure (SBP)

Conditions studied

Hypertension

Every field above is taken directly from the registry record. See all detected changes across the class, or the orforglipron page for this molecule’s full trial and approval history.